basiliximab + methylprednisolone + RATG + cyclosporine + mycophenolate mofetil

This is a combination immunosuppressive regimen used primarily in organ transplantation to prevent rejection. It combines five different immunosuppressive agents with complementary mechanisms of action: - **Basiliximab**: A chimeric monoclonal antibody that targets the IL-2 receptor alpha chain (CD25) on activated T-lymphocytes, preventing IL-2 binding and T-cell proliferation - **Methylprednisolone**: A corticosteroid with broad anti-inflammatory and immunosuppressive properties - **RATG (Rabbit Anti-Thymocyte Globulin)**: A polyclonal antibody preparation that depletes T-lymphocytes - **Cyclosporine**: A calcineurin inhibitor that prevents T-cell activation by inhibiting interleukin-2 production - **Mycophenolate mofetil**: An antiproliferative agent that inhibits de novo purine synthesis, affecting T and B lymphocyte proliferation This multi-drug protocol is designed to provide comprehensive immunosuppression through multiple pathways, allowing for reduced doses of individual components to minimize side effects while maintaining efficacy in preventing organ rejection.